2159123-14-3
2159123-14-3
Chemical Structure
PF-06939999
Synonym(s): PRMT5-IN-3
- CAS No.: 2159123-14-3
- Formula:C22H23F3N4O3
- Molecular Weight:448.44
IUPAC Name: (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
InChIKey: HBGHQRGHFNTSDP-DJABAAGCSA-N
SMILES: O[C@@H]1[C@H](O)[C@@H](OC2=CC(C(F)F)=C(F)C3=C2CNCC3)C[C@H]1N4C=CC5=C(C)N=CN=C54
Biological Activity: PF-06939999 (PRMT5-IN-3) is a SAM-competitive, orally active PRMT5 inhibitor that inhibits the expression of SDMA protein (IC50 in A427 is 1.1 nM). PF-06939999 exhibits antitumor effect[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PF-06939999 | 99.84% | PF-06939999 (PRMT5-IN-3) is a SAM-competitive, orally active PRMT5 inhibitor that inhibits the expression of SDMA protein (IC50 in A427 is 1.1 nM). PF-06939999 exhibits antitumor effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Adli M. Combinatorial drug treatment of cancer. WO2020198601A1.
- [2]. Jensen-Pergakes K, et al., SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance. Mol Cancer Ther. 2022 Jan;21(1):3-15. [Content Brief]
